We are live on
!
Find out more
Voloridge Investment Management Portfolio holdings
AUM
$25B
1-Year Est. Return
28.08%
This Fund
S&P 500
This Quarter
Est. Return
+6.27%
1 Year Est. Return
+28.08%
3 Year Est. Return
+85.2%
5 Year Est. Return
+73.43%
10 Year Est. Return
+582.16%
AUM
$17.9B
AUM Growth
-$597M
(-3.2%)
Cap. Flow
-$1.32B
Cap. Flow
% of AUM
-7.36%
Top 10 Holdings %
Top 10 Hldgs %
8.81%
Holding
1,709
New
345
Increased
450
Reduced
603
Closed
311
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$146M |
| 2 |
Apple
AAPL
|
+$129M |
| 3 |
Tesla
TSLA
|
+$110M |
| 4 |
Medtronic
MDT
|
+$104M |
| 5 |
Verizon
VZ
|
+$102M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class B
BRK.B
|
+$181M |
| 2 |
Microsoft
MSFT
|
+$177M |
| 3 |
Comcast
CMCSA
|
+$173M |
| 4 |
Adobe
ADBE
|
+$163M |
| 5 |
Broadcom
AVGO
|
+$157M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.34% |
| 2 | Healthcare | 14.31% |
| 3 | Consumer Discretionary | 12.9% |
| 4 | Industrials | 11.52% |
| 5 | Financials | 10.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CPRX
451
DELISTED
Catalyst Pharmaceutical
CPRX
| $9.42M | 0.05% |
506,496
-210,250
| -29% | -$3.24M |
|
|
EQC
452
DELISTED
Equity Commonwealth
EQC
| $9.3M | 0.05% |
372,579
+53,209
| +17% | +$1.36M |
|
453
Sylvamo
SLVM
$1.53B
| $9.25M | 0.05% |
190,403
-17,744
| -9% | -$852K |
|
454
Petrobras Class A
PBR.A
$103B
| $9.25M | 0.05% |
995,684
-1,089,256
| -52% | -$11.7M |
|
455
PACCAR
PCAR
$69B
| $9.19M | 0.05% |
+139,248
| New | +$9.1M |
|
456
Alibaba
BABA
$300B
| $9.16M | 0.05% |
+103,993
| New | +$8.2M |
|
|
ABB
457
DELISTED
ABB Ltd
ABB
| $9.15M | 0.05% |
300,534
+18,770
| +7% | +$546K |
|
|
SEE
458
DELISTED
Sealed Air
SEE
| $9.13M | 0.05% |
182,980
-57,254
| -24% | -$2.79M |
|
459
Delta Air Lines
DAL
$59.1B
| $9.1M | 0.05% |
276,814
-388,572
| -58% | -$12.9M |
|
460
C3.ai
AI
$1.57B
| $9.05M | 0.05% |
808,938
+275,647
| +52% | +$3.45M |
|
461
Goldman Sachs
GS
$302B
| $9.04M | 0.05% |
+26,320
| New | +$9.16M |
|
462
Valmont Industries
VMI
$9.52B
| $8.95M | 0.05% |
27,057
+10,381
| +62% | +$3.29M |
|
463
CoStar Group
CSGP
$12.4B
| $8.93M | 0.05% |
+115,493
| New | +$9.02M |
|
|
GOGL
464
DELISTED
Golden Ocean Group
GOGL
| $8.91M | 0.05% |
1,025,024
-482,564
| -32% | -$4.19M |
|
465
AbbVie
ABBV
$440B
| $8.87M | 0.05% |
54,862
-276,979
| -83% | -$42.5M |
|
466
GlobalFoundries
GFS
$29.2B
| $8.85M | 0.05% |
+164,157
| New | +$9.59M |
|
467
Qiagen
QGEN
$8.88B
| $8.77M | 0.05% |
165,851
+125,858
| +315% | +$6.2M |
|
468
Winnebago Industries
WGO
$915M
| $8.65M | 0.05% |
164,121
-72,169
| -31% | -$4.1M |
|
469
Evergy
EVRG
$19.2B
| $8.63M | 0.05% |
137,131
-7,947
| -5% | -$477K |
|
470
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$5.37B
| $8.61M | 0.05% |
297,152
+15,832
| +6% | +$461K |
|
|
BLUE
471
DELISTED
bluebird bio
BLUE
| $8.59M | 0.05% |
62,039
+36,152
| +140% | +$5.09M |
|
472
Integra LifeSciences
IART
$1.35B
| $8.58M | 0.05% |
152,989
-66,807
| -30% | -$3.4M |
|
473
ITT
ITT
$19.4B
| $8.56M | 0.05% |
105,547
-62,136
| -37% | -$4.81M |
|
|
WBA
474
DELISTED
Walgreens Boots Alliance
WBA
| $8.55M | 0.05% |
+228,799
| New | +$8.6M |
|
475
Donaldson
DCI
$11.2B
| $8.54M | 0.05% |
145,033
+3,253
| +2% | +$186K |
|
Similar funds
VAI
Voloridge Investment Management's Q4 2022 Portfolio in Review
As of Q4 2022, Voloridge Investment Management held 1,709 positions worth $17.9B, down 3.2% from $18.5B the previous quarter. Its ten largest holdings account for 8.8% of the portfolio.
Voloridge Investment Management withdrew a net $1.32B in Q4 2022, closing 311 positions and reducing 603 holdings. Its most notable exit was Berkshire Hathaway Class B, an estimated $181M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Voloridge Investment Management opened a new position in Edwards Lifesciences worth $142M.
- Voloridge Investment Management's largest Q4 2022 buy was Edwards Lifesciences: 1,898,822 shares worth $142M.
- Voloridge Investment Management added most to Tesla in Q4 2022, an estimated $110M increase.
- Voloridge Investment Management's biggest Q4 2022 reduction was Microsoft, cutting an estimated $177M.
- Voloridge Investment Management fully exited Berkshire Hathaway Class B in Q4 2022, selling an estimated $181M.
- Voloridge Investment Management's ten largest holdings make up 8.8% of its $17.9B portfolio in Q4 2022.
- Voloridge Investment Management opened 345 new positions and closed 311 in Q4 2022.
- Voloridge Investment Management's portfolio value fell 3.2% quarter-over-quarter to $17.9B.
Based on Voloridge Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.